Viral gene transfer

Gene transfer techniques are an important tool in studies of gene function as well as in the clinical evaluation of new treatments. In research the most important impact of efficient transient and stable gene transfer methods is the generation of new cell lines or animal models for the basic research of protein functions. Many of these methods are based on utilization of viruses as means to target and deliver genes into appropriate cells. Alternatively, recent advances in the RNAi-methodology enable the same delivery method to be used to efficiently silence specific genes in cells.

Successful work with sophisticated viral methods requires special expertise and strict safety considerations both of which are found at all of the biocenters in Finland.

Contact persons & Feedback

Technology platform services

Viral gene transfer and cell therapy

Service providers

BCK National Virus Vector Core Facility
- Production of adenoviral, lentiviral, AAV and baculoviral vectors for in vitro and in vivo work.
- Training of researchers for in vitro and in vivo animal gene transfer methods.

Biomedicum Functional Genomics Unit (FuGU)
- Recombinant virus services (lenti and retroviruses)

AAV Gene Transfer and Cell Therapy Core Facility
- Recombinant adeno-associated virus (AAV) preps.

Cancer gene therapy group
- oncolytic viruses

Biocenter Oulu Virus Vector Core Facility
- Production of adeno and lentiviruses

Viral Vector Facility
- recombinant viral (Lenti and Adeno) vectors

BMT Tampere Virus Vector Facility
- Small and medium scale virus production (retro and lentiviruses)

Also University of Jyväskylä Vector Core facility participates in the Biocenter Finland National Imaging Infrastructure Network activities: Live and still virus imaging (external member), Jyväskylä Environmental and Nanoscience Center, University of Jyväskylä, Maija Vihinen-Ranta

Tissue engineered disease models

TEDM is an emerging technology platform focusing on development of complex ex vivo and in vivo tissue models compatible with genetic and chemical biology approaches. The targeted tissues are mammary gland and lung epithelial organs, and vascular and lymphoid systems. In Biocenter Finland, TEDM's focus complements existing virus, drug discovery and animal models networks. Read more about TEDM on Model organisms section.

Contact persons & Feedback

Viral gene transfer & cell therapy technology platform user survey

Viral gene transfer and cell therapy technology platform user survey

Contact persons

Coordinator of the BF Viral Gene Transfer and Cell Therapy Infrastructure Network
Seppo Ylä-Herttuala / tel. +358 40 355 2075 / seppo.ylaherttuala(at)
Biocenter Kuopio, University of Eastern Finland
The A. I. Virtanen Institute, Molecular Medicine Research Group
National Virus Vector Laboratory

Viral Gene Transfer and Cell Therapy Technology Platform (VGTCT) partners:
Seppo Ylä-Herttuala (Chair of the consortium), BCK, National Virus Core Facility, A. I. Virtanen Institute; Kari Alitalo, BCH, AAV Gene Transfer and Cell Therapy Core Facility; Akseli Hemminki, BCH, Oncolytic vector core facility; Juha Klefström, BCH, Functional Genomics Unit (FuGu); Aki Manninen, BCO, Virus Vector Core Facility; Eric Dufour, BMT Virus Vector Facility; Eleanor Coffey, BioCity, Viral Vector Facility. External member: Maija Vihinen-Ranta, University of Jyväskylä